Genetic test for chemotherapy response in breast cancer
Part of Cancer, Skin clinical trials.
This study looks at whether a specific gene (called CASP3) affects how well breast cancer responds to chemotherapy. By joining, you may help doctors understand why some treatments work better for some people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female.
- You have been newly diagnosed with breast cancer.
- You are a patient at South Egypt Cancer Institute.
- You do not have any other type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genomic tests (which analyze your tumor's genes) are used in routine care for early-stage breast cancer that is hormone-sensitive. It may help doctors understand who really needs chemotherapy in addition to hormone therapy.
This study uses genetic testing of your tumor to find specific mutations and match you with targeted therapies, aiming to improve outcomes for advanced cancers with poor prognosis. If you have pancreatic, liver, or triple negative breast cancer and are starting treatment, this trial may help you access personalized treatment options.
This study looks at tiny particles in your blood and tumor to see if they can predict how well your chemotherapy will work for breast cancer. The goal is to help guide treatment based on your individual cancer.
This study looks at the genetic changes in breast cancer patients, especially those with a family history or early onset. It may help doctors understand which genes are common in Chinese breast cancer patients and guide future treatment options.
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.